Antibody Production Assay
Antibody Production Assay - Related Videos
09:54
Laboratory Scale Production and Purification of a Therapeutic Antibody
0 Views •
Cited by 9 •
2017
This protocol describes the production of a therapeutic antibody in a mammalian expression system. The methods described include preparation of vector DNA, stable transfection and serum-free adaptation of a human embryonic kidney 293 cell line, set up of large scale cultures and purification using affinity chromatography.
08:11
Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay
0 Views •
Cited by 54 •
2016
We describe the enzyme-linked lectin assay (ELLA) for measuring influenza neuraminidase (NA)-inhibition antibody titers in sera. The assay uses peanut agglutinin to quantify galactose residues that become accessible when NA removes sialic acid from fetuin-coated, 96-well plates.
02:29
Antibody Production from a Batch Overgrowth Culture of Transfected Mammalian Cells
0 Views •
2025
The video demonstrates a method for producing therapeutic antibodies using stably transfected mammalian cells. Tryptone supplementation stimulates cell division, resulting in overgrowth and supporting a higher antibody yield. The antibody-containing medium is harvested, filtered, and stored for further use.
03:22
Production and Purification of Recombinant Antibodies from Mammalian Cells
0 Views •
2025
The video explains the process of producing antibodies in mammalian host cells, from gene expression to secretion. It involves transcription, translation, signal recognition, correct folding, and eventual release into the extracellular medium via secretory vesicles.
03:19
An Assay to Measure Influenza Neuraminidase Inhibition Antibody Titers
0 Views •
2025
This video demonstrates an assay measuring influenza neuraminidase (NA) inhibiting antibody titers in a serum sample. A serum sample containing antibodies against NA is added to a fetuin-coated microwell plate. Upon adding the virus, the antibodies prevent viral NA from cleaving fetuin and exposing its galactose moiety. A peroxidase-conjugated lectin is then added, which binds to the exposed galactose. The NA-inhibiting antibody titer is determined using a colorimetric test, where a peroxidase...
FAQs
Specificity comes from matching the assay’s antigen to the antibody response being investigated. Antibodies that recognize that antigen bind during the detection step, and a binding-based readout such as an enzyme-linked immunosorbent assay converts that interaction into a measurable signal. This allows investigators to distinguish the presence and amount of antigen-directed antibody from a broader, nonspecific response.
Antigen selection, the stimulus applied to antibody-producing cells, the biological sample examined, and the timing of measurement can all shape the result. These choices determine whether the assay emphasizes how much antibody is produced, which antigen it recognizes, or when the response becomes detectable. Consequently, assay conditions must match the specific immune question being studied.
Changing the antigen changes the binding target used for detection, so the assay can examine whether antibodies recognize one antigen rather than another. This is particularly useful when researchers need to characterize immune responses rather than report only overall antibody production. The resulting specificity information helps distinguish a targeted humoral response from a measurement that lacks antigen-level resolution.
A typical design selects the relevant antigen, applies the planned stimulus when antibody-producing cells are being evaluated, and uses a binding-based detection method to measure antigen-specific antibodies. Enzyme-linked immunosorbent assay formats provide one example of the detection stage. Organizing the workflow around antigen, stimulus, and readout helps align the measurement with the intended immune response.
After vaccination, the assay can characterize the magnitude and antigen specificity of the resulting humoral response. Measurements at different time points can also show when the response becomes detectable and how it changes over time. Thus, the method provides more than a single antibody value, linking vaccine-related immune activation to response timing and target recognition.
It can help monitor infection-associated immunity and assess therapeutic antibody production. In infection studies, antigen-specific measurements can describe the immune response associated with an infectious agent. In therapeutic research, the same quantitative framework can be directed toward antibody production as an experimental outcome, allowing investigators to compare the magnitude and specificity of responses.